SOURCE: Marathon Patent Group

Marathon Patent Group

April 07, 2015 09:00 ET

Marathon Patent Group's Wholly-Owned Subsidiary Sarif Biomedical, LLC Enters Into Settlement and License Agreement With Varian Medical Systems, Inc.

LOS ANGELES, CA--(Marketwired - Apr 7, 2015) - Marathon Patent Group, Inc. (NASDAQ: MARA) ("Marathon"), a patent licensing company, announced today that its wholly-owned subsidiary, Sarif Biomedical LLC, ("Sarif"), has entered into a settlement and license agreement with Varian Medical Systems, Inc. ("Varian"). The consideration to be paid by Varian to Sarif and all other commercial terms of the license agreement are confidential.

The Sarif portfolio relates to microsurgery methods and related equipment including articulated tools, imaging systems and displays as well as sensors employed as integral parts of the system. Additionally, along with the U.S. patents, the portfolio includes the patent claims for the European counterparts. The patents include U. S. patent number 5,755,725 entitled "Computer-assisted microsurgery methods and equipment" and the European counterparts including Germany, France, and Great Britain.

About Marathon Patent Group:
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.

Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information